Reports Q4 revenue $2.6M, consensus $2.55M. “Nuwellis continues to execute on its strategic growth initiatives, with the highest total quarter of organic revenue in company history,” said Nestor Jaramillo, President and CEO of Nuwellis. “Led by Pediatrics, which saw steady increases in existing console utilization and new account openings expanded Aquadex market penetration. We expect our accelerating momentum to continue in 2024, with further support from our growing body of clinical evidence, paving the way for new Aquadex applications such as in end-stage liver disease, as well as new product introductions.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NUWE:
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
- Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
- NUWE Earnings this Week: How Will it Perform?
- Nuwellis partner SeaStar Medical receives FDA HDE for Quelimmune
- Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)